Home | Contact
Deciphera in the News Deciphera logo
A pharmaceutical firm that moved to Lawrence from Cambridge, Mass., earlier this year has raised $15 million from private Kansas investors. Deciphera Pharmaceuticals, which is developing drugs to attack the molecular cause of Alzheimer's disease, rheumatoid arthritis, asthma and other diseases...”
- The Kansas City Star, December 19, 2003

Presentations

Cellular mechanistic studies of novel inhibitors of the T315I mutant of BCR-ABL - American Association for Cancer Research 2008 Annual Meeting, San Diego, CA April 12-16th 2008

Second generation inhibitors of BCR-ABL kinase switch pockets for treatment of chronic myelogenous leukemia: Optimizing the kinome fingerprint - American Association for Cancer Research 2008 Annual Meeting, San Diego, CA April 12-16th 2008

Activation switch pocket inhibitors target the T315I mutant of BCR-ABL - American Association for Cancer Research 2008 Annual Meeting, San Diego, CA April 12-16th 2008

DCC-2036: A novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy against BCR-ABL T315I in vitro and in a CML mouse model - American Society of Hematology, Atlanta , Georgia , December 8-11, 2007

Inhibitors targeting the conformational switching pocket of V600E oncogenic BRAF kinase: Preclinical evaluation of DP-2514 and related analogs - Invited presentation at the 4th International Melanoma Congress, New York City , November 1-4th 2007

Small molecule modulators of BRAF conformational switching pockets for treatment of human cancers. Inhibitors of wt and V600E, T529I/V600E mutant forms. AACR-NCI-EORTC International Conference for Molecular Targets and Cancer Therapeutics. San Francisco, CA. October 22-26, 2007.

6th International Annual Protein Kinase conference, Loews Coronado Hotel, San Diego, CA October 17th-19th, 2007.

Discovery and development of kinase inhibitors by targeting conformational switch pockets. A general platform that is unique from targeting ATP pockets - Invited presentation at the International Symposium of the Asian Federation of Medicinal Chemistry, St. Petersburg, Russia, August 27-31, 2007.

Targeting kinase switch pockets: 1) Deciphera's approach to kinase regulation; 2) Development of selective and multi-kinase targeted B-Raf inhibitors -Invited presentation at the American Chemical Society National Meeting, Boston, Massachusetts, August 19-23, 2007.

Development of inhibitors of BCR-ABL kinase which target T315I and other significant mutants - Invited presentation at The 6th Annual Congress: Protein kinases in discovery and early drug development, Lisbon, Portugal, May 22-23, 2007.

Regulation of kinases by small molecules: Binding into biomimetic conformational switching pockets - Invited presentation at Drug Discovery Technology Europe, London UK, March 12-15, 2007.

Mimicry of endogenous kinase regulation. Small molecule modulators of kinase conformational switching pockets - Invited presentation at the 8th Winter Conference on Medicinal and Bioorganic Chemistry, Steamboat Springs, Colorado, January 21-25, 2007.



Deciphera Pharmaceuticals, LLC
4950 Research Park Way
Lawrence, KS 66047

785-838-3767 phone
785-838-3747 fax
info@deciphera.com

Home | Fact Sheet | Senior Management | Board of Managers | Scientific Advisory Board | Platform | Pipeline | Oncology | Metabolic
BCR-ABL | BRAF | News | Presentations | Careers | Location | Partners | Contact | Directions